We’re delighted to announce a Research Partnership study into payers perspectives on the acceptability of surrogate endpoints for acute conditions managed in the ICU has been selected by The Professional Society for Health Economics and Outcomes Research for a poster presentation at the ISPOR Europe 2022 conference, 6-9 November in Vienna, Austria.
The poster, which is entitled, ‘The challenges of generating patient-relevant outcomes and other evidence sufficient to satisfy European HTA bodies in acute conditions managed in the ICU’ is authored by Market Access Director Rachel Howard and Associate Consultant Rebeca Nana Barrantes in partnership with Andrew Sims from Advanz Pharma.
About our poster
The challenges of generating patient-relevant outcomes and other evidence sufficient to satisfy European HTA bodies in acute conditions managed in the ICU
In recent years, there has been considerable discussion around the acceptability of surrogate endpoints in oncology. However, other therapeutic areas also use such endpoints to measure patients’ improvement. It is particularly challenging to measure treatment effects when conducting clinical trials in acute conditions in the intensive care (ICU) setting. To evaluate the acceptability of an endpoint related to arterial pressure as a primary endpoint in HTA submissions, focus groups and online surveys were conducted with (proxy) payers and leading ICU clinicians across France, Germany, Italy, Spain, and UK.